Krystal Biotech (KRYS) return on equity (ROE)

Return on equity · fiscal 2025
16.8%

Krystal Biotech (KRYS) earned a return on equity of 16.8% in fiscal 2025 (the year ended December 31, 2025). That is 7.4 percentage points higher than the 9.4% of fiscal 2024. Figures as of 18 Nov 2026, 00:20 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
16.8%
Change on fiscal 2024
+7.4 pts
Highest on record
16.8%fiscal 2025
Lowest on record
-397.9%fiscal 2016
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Krystal Biotech return on equity (ROE), in more detail

Across the 10 fiscal years on record (2016–2025), the highest was 16.8% in fiscal 2025 and the lowest -397.9% in fiscal 2016. The fiscal 2025 figure is higher than in every one of the 9 earlier fiscal years on record, whose median is -11.0%.

History · 10 fiscal years

Return on equity by fiscal year

Krystal Biotech return on equity (ROE), year by year

Krystal Biotech (KRYS) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202516.8% 7.4 pts up
20249.4% 8.0 pts up
20231.4% 28.2 pts up
2022-26.8% 15.1 pts down
2021-11.7% 0.7 pts down
2020-11.0% 1.6 pts down
2019-9.4% 0.2 pts up
2018-9.6% 6.4 pts up
2017-16.0% 381.9 pts up
2016-397.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Krystal Biotech and comparable companies
CompanyReturn on equityFiscal year
Praxis Precision Medicines PRAX-34.5%2025
Twist Bioscience TWST-16.4%2025
Protagonist Therapeutics PTGX-21.2%2025
Krystal Biotech KRYS16.8%2025
10x Genomics TXG-5.5%2025
HealthEquity HQY10.2%2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KRYS

Krystal Biotech, figure by figure

Krystal Biotech (KRYS) overview: price, valuation and scorecardAll health care companies by market value

Krystal Biotech return on equity (ROE): questions and answers

What is Krystal Biotech's return on equity?

Krystal Biotech (KRYS) earned a return on equity of 16.8% in fiscal 2025 (the year ended December 31, 2025). That is 7.4 percentage points higher than the 9.4% of fiscal 2024.

Is Krystal Biotech's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in every one of the 9 earlier fiscal years on record, whose median is -11.0%.

What are the highest and lowest return on equity figures on record for Krystal Biotech?

Across the 10 fiscal years on record (2016–2025), the highest was 16.8% in fiscal 2025 and the lowest -397.9% in fiscal 2016.

How is Krystal Biotech's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Krystal Biotech (KRYS) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/KRYS/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.